JS001 Combination Therapy in NSCLC Negative Driving Gene After First-line Chemotherapy.

Inclusion Criteria: 1. Signed the informed consent form (ICF); 2. Recurrent or advanced stage Ⅲ B or IV non-small cell lung cancer tested for EGFR mutation and ALK, ROS1 fusion gene, and all the driving gene was negative. 3. At least one measurable lesion (according to RECIST 1.1); 4. Failure of previous first-line standard chemotherapy: 5. Patients who agreed to provide previously stored tumor tissue specimens or fresh biopsies of tumor lesions 6. Age 18-75 years old, regardless of gender; 7. ECOG score 0-1; 8. Expected survival time ≥ 3 months; 9. Laboratory test value must show enough organ function Exclusion Criteria: 1. Tumor histology or cytological pathology confirmed the presence of small cell lung cancer components, or sarcomatoid lesions; 2. Those who did not have a driving gene test; 3. Investigator believed that there was a clear bleeding tendency 4. Subjects who are currently participating in and receiving treatment in other studies, less than 4 weeks 5. Patients who had previously received second-line or more systemic chemotherapy for advanced NSCLC; 6. Patients who had received hematopoietic stimulating factors, within one week before the start of the study. 7. Uncontrollable or symptomatic hypercalcemia 8. Within 6 months before receiving the study treatment, they received chest (lung) radiotherapy \> 30Gy, or received radiotherapy within 4 weeks or radiopharmaceuticals within 8 weeks, except for local palliative radiotherapy for bone metastases. 9. The adverse reactions of previous antineoplastic therapy have not yet recovered to CTCAE 5.0 grade ≤ 1 (except alopecia); 10. Major surgery or radiotherapy has been performed within 4 weeks before joining the group or has not yet fully recovered from the previous operation 11. Known active central nervous system (CNS) metastasis and / or cancerous meningitis; 12. Spinal cord compression without radical treatment of surgery and / or radiotherapy; 13. Uncontrolled tumor-related pain; 14. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage ; 15. Evidence of active pneumonia was found; 16. Clinically uncontrolled active infections; 17. Uncontrollable major seizures or superior vena cava syndrome; 18. Past or present co-existence of other malignant tumors; 19. Liver diseases known to be of clinical significance; 20. Those who have previously used any anti-PD-1 antibody, anti-PD-L1 antibody, anti-PD-L2 antibody or anti-CTLA-4 antibody and Axitinib; 21. Patients with active tuberculosis (TB); 22. Patients with any active autoimmune disease or history of autoimmune disease; 23. Any anti-infective vaccine; 24. Known (HIV) infection of human immunodeficiency virus; 25. The researchers believe that it can affect study compliance; 26. Patients who received systemic immunosuppressive drugs within the first 4 weeks of the first day of the first cycle; 27. History of severe allergy, anaphylaxis or other hypersensitivity to chimeric or humanized antibodies or fusion proteins; 28. Those who are known to be allergic to biological drugs; 29. Those who are known to be allergic to acitinib; 30. Patients with a history of arterial or venous thromboembolism; 31. Known hereditary or acquired bleeding and thrombotic tendencies; 32. Patients who have previously received allogeneic stem cell or parenchyma organ transplantation; 33. Pregnant or lactating women or women of childbearing age who were positive for serum pregnancy test before taking the drug for the first time